Jujubosides

Jujubosides: A Comprehensive Reference

1. Identity, Botanical Source, and Chemical Characterization

1.1 Botanical Source

Jujubosides are a family of dammarane-type triterpenoid saponins principally isolated from the seeds of Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chow, a member of the family Rhamnaceae, taxonomically authenticated as Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chow. Ziziphus jujuba is a deciduous tree originating from China; its seeds have been used in traditional Chinese medicine for centuries and possess many healing properties. In Chinese materia medica the seeds are known as Suan Zao Ren (酸枣仁), a designation that distinguishes them from the sweet red jujube fruit consumed as food. The entire plant possesses medicinal and edible utility; the seed, known as Suanzaoren in traditional Chinese medicine, is a medicinal food homolog. It is sweet in taste and neutral in nature, and is used to nourish the liver, calm the heart, arrest sweating, and promote fluid production, primarily for treating conditions such as insomnia, palpitations, night sweats, and thirst due to fluid deficiency.

1.2 Chemical Identity and Structural Classification

Tetracyclic triterpenoid saponins are mainly found in Ziziphus jujuba var. spinosa seeds (ZSS) but are less abundant in leaves and fruits. A total of 21 saponins are present in seeds as the dammarane type. Among them, jujuboside A and jujuboside B were the first discovered saponin compounds in 1978. Later, jujuboside A1, jujuboside B1, jujuboside C, acetyljujuboside B, protojujuboside A, protojujuboside B, and protojujuboside B1 were isolated from ZSS by researchers. A novel triterpenoid saponin, jujuboside I, together with five known compounds — jujuboside A, jujuboside B, jujuboside C, betulin, and betulinic acid — were isolated from Semen Ziziphi Spinosae, the seeds of Ziziphus jujuba var. spinosa (Bunge) Hu ex H. F. Chou.

Jujuboside A (JuA) is a triterpenoid saponin isolated from Semen Ziziphus spinosae. It is the primary active component of the mature seed of wild Ziziphus jujuba. Jujuboside B (JuB) is a natural saponin triterpenoid found in the fruit plant Ziziphus jujuba Mill. This plant's fruit is reported to have physiological effects ranging from anticancer to anti-inflammatory to antioxidant. Research involving jujubosides A and B is the most active, since the two compounds have various biological properties.

Chemically, the seeds are characterized by flavonoid-C-glycosides (e.g., spinosin), dammarane-type triterpenoid saponins (e.g., jujubosides A and B), and cyclic peptide alkaloids. Twenty-two compounds have been identified in ethanol extracts of Ziziphus jujuba Mill, and results imply that the Chinese jujube is rich in glycosides, flavonoids, nucleosides, organic acids, and saponins. The aglycone (sapogenin) released upon hydrolysis of jujuboside A is known as jujubogenin. There have been reports suggesting that not JuA itself, but its metabolite jujubogenin, may be responsible for the sedative bioactivity through interacting with GABA(A) receptors.

1.3 Common Forms and Preparations

ZSS is mainly used for medicinal purposes in the form of capsules, tablets, and liquid extracts as an herb to treat depression and insomnia. In at least one clinical study, raw ZSS seeds were processed and extracted using 100% water, producing a 5-to-1 herbal drug-to-extract ratio; all ZS capsules contained 65% ZS concentrated extract and 35% corn starch. The ZS extract in that study was tested for active ingredients using HPLC analysis and included jujuboside A (0.113 mg/g) and jujuboside B (0.124 mg/g). The herb also appears as a component of traditional multi-herb decoctions such as Suan Zao Ren Tang. Jujuboside A, isolated from Suanzaoren, is considered one of the most important pharmacological molecules responsible for insomnia therapy. The Suanzaoren decoction is made up of five herbs: Semen Ziziphus spinosae, Rhizoma chuanxiong, Poria, Rhizoma anemarrhenae, and Radix glycyrrhizae, with the dried seed of Ziziphus jujuba being the main ingredient. Fermentation of jujube seed extract enhances the bioavailability of its bioactive compounds by 3.2-fold compared to non-fermented extracts, according to one cited preclinical source.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine

ZSS is a traditional Chinese herb used for both medicine and food and was first recorded in Shennong's Classic of Materia Medica. It has been used for the treatment of insomnia for thousands of years in China. Ziziphus jujuba's mention dates back over 3,000 years in ancient Chinese medical texts like the Shen Nong Ben Cao Jing (circa 100 AD). The Shennong Bencao Jing (ca. 200 CE) lists Suan Zao Ren as a superior class herb, describing it as useful for "quieting the five Zang, securing the Spirit, and preventing loss of essence." Zhang Zhongjing's Jin Gui Yao Lue (ca. 220 CE) introduces the canonical formula for Liver Blood and Yin deficiency insomnia with vexation, and the formula's enduring popularity marks the seed's status as a formula-defining chief herb.

The seed is described in traditional Chinese medicine as sweet in taste and neutral in nature, used to nourish the liver, calm the heart, arrest sweating, and promote fluid production, primarily for treating conditions such as insomnia, palpitations, night sweats, and thirst due to fluid deficiency. The most frequently used herb for insomnia is the seed of Ziziphus jujuba Mill. var. spinosa (Bunge) Hu ex H. F. Chou, and the most common herbal formulae include Suan Zao Ren Tang and Wen Dan Tang, which are consistent with current clinical practice. The mature seed of Ziziphus jujuba and Ziziphus spinosae is widely used in China, Japan, Korea, and other oriental countries for medicinal purposes.

2.2 Traditional Use in Other Cultures

In India's Ayurvedic compendia, though less extensively catalogued than in Traditional Chinese Medicine (TCM), jujube appears in regional folk-healing manuscripts. Persian physician Avicenna (Ibn Sina) in his Canon of Medicine praised jujube's gastric benefits, recommending it for indigestion and to "steady the heart." Ziziphus jujuba is widely used in traditional Cameroonian medicine to treat diabetes, pain, infections, and dementia. It is widely used in the Indo-Pakistani subcontinent as food, fodder, nutrition, medicine, building material, and fuel.

3. Key Constituents and Established Mechanisms of Action

3.1 The Jujuboside Family

Many compounds have been identified in ZSS, including terpenoids, alkaloids, flavonoids, fatty acids, volatile oils, and polysaccharides. Among these, the jujuboside saponins — most prominently jujuboside A and jujuboside B — are considered the primary pharmacologically active fraction. Jujuboside A has been reported to have multiple properties, including antioxidant, anti-inflammatory, anti-anxiety, hypnotic-sedative, and anti-apoptosis capacities. The sedative-hypnotic capacity of jujuboside B is also a major characteristic of that compound. Overall, jujubosides A and B, rather than other constituents of jujube, have therapeutic potential in multiple organs and tissues, and translational scientists are just beginning to reveal their mechanisms.

3.2 GABAergic and Glutamatergic Mechanisms

The most thoroughly studied mechanism of action for jujubosides involves modulation of inhibitory and excitatory neurotransmitter systems. Jujuboside A and jujuboside B have significant effects on the expression and activation of GABA-A receptors; low-dose jujuboside A induced significant increases in the mRNA of α1, α5, and β2 subunits of GABA-A receptor in both 24-hour and 72-hour treatments, and increased the frequency of the opening of chloride channels, which produced a calming and hypnotic effect. Jujuboside A upregulates GABA levels while suppressing glutamate and neuronal apoptosis, with concomitant increases in GABA-A and GABA-B receptor expression. GABA blockade (GABA-IN-1) abolished these therapeutic effects, confirming GABA dependency.

In a study using a penicillin sodium-induced hyperactivity rat model, cortical EEG and the concentration of hippocampal glutamate (Glu) were monitored simultaneously in vivo. JuA (0.05 g/L and 0.1 g/L) inhibited the EEG excitation effect by increasing the power of δ1 and δ2 bands (p<0.01 vs model) and lowering the gravity frequency of power spectral density; JuA also remarkably reduced the Glu elevation induced by Na-PCN (p<0.05 vs model). JuA has an inhibitory effect on the rat hippocampal formation in vivo and in vitro and decreases the slopes of excitatory postsynaptic potential through the glutamate-mediated excitatory signal pathway. It can also modulate the expression of GABA receptor subunit genes in hippocampal neurons.

GABAergic inhibitory mechanisms are crucial for the initiation and maintenance of sleep. Results from electrophysiological experiments reveal that puff application of JuA on hippocampal CA1 neurons evoked a tonic GABA current-like response in a dose-dependent manner, suggesting that JuA may improve sleep loss-induced behavioral and hippocampal molecular abnormalities via increasing GABAergic inhibition and thus maintaining proper excitation/inhibition balance.

3.3 Serotonergic Mechanisms

Suanzaoren contains complex mixtures of phytochemicals including sanjoinine A, jujuboside A, spinosin, and other flavonoids, which have sedative and hypnotic functions primarily mediated by the GABAergic and serotonergic system. FSZR (formula of Suanzaoren) exerted sedative and hypnotic actions mainly through the GABAergic and serotonergic system. The interaction between jujubosides and serotonin (5-HT) receptors is understood to complement GABAergic activity, though the precise receptor subtype selectivity in humans has not been fully delineated in clinical studies.

3.4 Metabolite Activity: Jujubogenin

Jujuboside B and jujubogenin — hydrolysis products of primary saponins — may be the absorbed bioactive species responsible for sedative effects via GABA-A receptor modulation. The role of gut microbiota in converting jujubosides to their active aglycones is an emerging area of study, discussed further under pharmacokinetics.

3.5 Neuroprotective Signaling Pathways

Jujuboside A has been shown to possess numerous positive effects, including antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective properties. Studies have demonstrated that JuA significantly upregulates the expression of proteins such as brain-derived neurotrophic factor (BDNF), tropomyosin receptor kinase B (TrkB), and cyclic-AMP response binding protein (CREB) in the hippocampus of corticosterone-induced depressed mice. Recent research has found that JuA has anti-injury and neuroprotective and cardioprotective activity via antioxidative and anti-inflammatory effects. The PI3K/AKT/mTOR pathway is one of the major signal transduction pathways responsible for regulating cell growth, proliferation, survival, and apoptosis.

4. Scientific Evidence by Area of Use

4.1 Sleep and Insomnia

Preclinical Evidence

Previous studies have reported that saponins have better sedative and hypnotic effects than flavonoids, because the former contributed to longer sleep time and shortened sleep latency in mice. Ziziphus jujuba var. spinosa, a traditional Chinese medicinal herb, has been historically used to treat insomnia and neurological disorders. Jujuboside A, a triterpenoid saponin isolated from ZSS, represents its core bioactive component with purported sedative properties, yet its mechanism of action remains underexplored. A 2025 study aimed to validate the anti-insomnia efficacy of jujuboside A and elucidate its GABAergic regulatory mechanisms through integrated in vivo and in vitro approaches, using a chronic sleep deprivation mouse model established with modified multi-platform water environment. Modern pharmacology has confirmed that ZSS has sedative and hypnotic, antidepressant, anxiolytic, and neuroprotective effects.

Clinical Evidence

Human clinical data on jujubosides specifically — as isolated compounds — are very limited. Most clinical research has been conducted on whole ZSS seed extracts or on the classical multi-herb formula Suan Zao Ren Tang (SZRT), making it difficult to attribute observed effects solely to the jujuboside fraction.

A role in the management of insomnia has been suggested in a review of pharmacological effects of the jujube seed, based on 2 small clinical studies. A meta-analysis of high-quality RCTs showed that FSZR monotherapy was superior to placebo (p<0.01); FSZR plus diazepam was superior to diazepam alone (p<0.05); there were mixed results comparing FSZR with diazepam (p>0.05 or p<0.05). Furthermore, FSZR caused fewer side effects than diazepam. A systematic review and meta-analysis of traditional herbal medicine (with Z. jujuba as the most frequently used herb) concluded that traditional herbal medicine may be an effective therapeutic option for insomnia in patients with cancer.

A randomized, placebo-controlled, crossover feasibility clinical trial of Ziziphus spinosa seeds for insomnia provided results based on data from 5 participants for some outcomes and 12 for others, underscoring the pilot nature of the study. The trial documented active-ingredient concentrations in the test product (jujuboside A at 0.113 mg/g and jujuboside B at 0.124 mg/g). Whole extracts and constituent compounds have been evaluated in preclinical and clinical studies. Z. spinosa secondary metabolites have shown to modulate GABAergic activity and the serotonergic system. The actual therapeutic agents require further confirmation and identification so that new insomnia phytomedicines can be discovered.

Despite promising preclinical findings, clinical validation of standardized fermented formulations remains limited, underscoring a critical research gap, particularly in translating these findings into effective human applications. Overall evidence strength for insomnia: Moderate for whole ZSS seed preparations and SZRT multi-herb formulae based on meta-analytic data; weak-to-preliminary for jujubosides as isolated compounds in humans, with no large-scale, high-quality RCTs specifically targeting jujuboside fractions.

4.2 Anxiety and Stress

Preclinical Evidence

Animal experiments using the saponin jujuboside and flavonoids from the fruits, as well as the seed extract, showed reductions in anxiety, impaired coordination and responses, and enhanced barbiturate-induced hypnotic effects. Jujuboside A/B (triterpenoid saponins) and flavonoids from wild jujube kernels have mechanistically demonstrated superior anxiolytic efficacy, establishing this botanical as a first-line phytotherapeutic agent for neuropsychiatric disorders in traditional Chinese medical treatment.

Overall evidence strength for anxiety: Preclinical (animal and cell-based) only; no specific published, adequately powered human RCTs on isolated jujubosides for anxiety have been identified in the peer-reviewed literature as of the time of this writing.

4.3 Depression

Preclinical Evidence

Depression is characterized by dysfunction of immature neurons, resulting in dysregulated calcium homeostasis and impaired structural plasticity. Jujuboside A, a biologically active compound derived from Semen Ziziphi Spinosae, has demonstrated anti-anxiety and anti-insomnia properties. Recent studies suggest that JuA may be a promising antidepressant, but its underlying mechanisms remain unclear. In one study, Sprague-Dawley rats were subjected to chronic unpredictable mild stress (CUMS) to induce a depression model. JuA (12.5 mg/kg, 25 mg/kg, 50 mg/kg) was administered orally for 4 weeks, and emotional and cognitive function were assessed. Studies demonstrated that JuA significantly upregulates the expression of BDNF, TrkB, and CREB in the hippocampus of corticosterone-induced depressed mice.

Overall evidence strength for depression: Preclinical only; evidence is preliminary and entirely derived from rodent models. No controlled human trials on isolated jujubosides for depression have been identified.

4.4 Cognitive Function and Neuroprotection (including Alzheimer's Disease)

Preclinical Evidence

Jujuboside A is a triterpene saponin isolated from Semen Ziziphi Spinosae and has been reported to have several biological activities including anti-oxidant, anti-inflammation, anti-apoptosis, and neuroprotection. A study demonstrated that JuA significantly restored function in APP/PS1 transgenic mice; after genetic ablation or pharmacological inhibition of potential target pathways, the target of JuA was discovered through the Axl/HSP90β pathway. After oral administration or intrathecal injection, the anti-AD activity of JuA was evaluated by Morris water maze (MWM) test and object recognition test. JuA significantly improves histopathological damage induced by β-amyloid 1–42 (Aβ1–42).

In a study of sleep-deprivation in young APP/PS1 mice (an Alzheimer's disease model), sleep deprivation caused spatial memory impairments and increased neuronal excitability. JuA suppressed sleep deprivation-induced enhancement of mEPSCs and prevented memory impairment in APP/PS1 mice; whole-cell puff experiments suggest that JuA activates GABAergic inhibition to reduce sleep-deprivation-induced enhancement of excitatory synaptic transmission.

Findings suggest that JuA promotes proliferation and neuronal differentiation of APP-overexpressing neural stem cells partly by activating the Wnt/β-catenin signaling pathway, pointing to a potential role in Alzheimer's disease.

Jujubosides protect against cerebral ischemic injury by reducing malondialdehyde (MDA) levels in the cerebrum of ischemia model rats, while also increasing the activities of superoxide dismutase (SOD), creatine kinase, and lactate dehydrogenase. Furthermore, they decrease lactate content and alleviate cerebral neuronal damage; jujubosides mitigate lipid peroxidation injury induced by cerebral ischemia, likely through enhanced SOD activity.

Overall evidence strength for cognitive function and AD: Preliminary; entirely preclinical (animal models and cell lines). These findings are scientifically suggestive but require human clinical trial validation before conclusions can be drawn.

4.5 Anti-inflammatory Effects

Total saponins from ZSS inhibit the release of TNF-α from RAW264.7 macrophages induced by LPS. ZSS also exhibits antidepressant, antidyslipidemia, hepatoprotective, anticardiomyocyte injury, immunoregulatory, cardiotonic, and neuroprotective effects in preclinical models. In cell-based studies, LPS-induced astrocyte damage was found to increase the release of inflammatory factors, disrupt glutamate and GABA transportation, and reduce production of BDNF.

Overall evidence strength for anti-inflammatory effects: Preclinical only; in vitro and animal evidence.

4.6 Anti-cancer Activity

Preclinical Evidence

In 2014, jujuboside B was first found to have anticancer activity, suppressing the proliferation of AGS and HCT116 cells via the activation of p38 and JNK-mediated apoptotic signals. In 2020, jujuboside B was found to trigger apoptosis in acute leukemia U937 cells via the RIPK1/RIPK3/MLKL signaling pathway. In 2021, jujuboside B was reported to induce apoptosis and autophagy in MDA-MB-231 and MCF-7 human breast cancer cells. More recently, jujuboside B was also found to induce ferroptosis and overcome radioresistance through the PPARγ-ATF3-Gpx4 signaling pathway in non-small cell lung cancer.

Overall evidence strength for anti-cancer effects: Preclinical only; all evidence is from in vitro cell-line studies and animal xenograft models. No human clinical data exist for jujubosides in oncology.

4.7 Cardiovascular and Cardioprotective Effects

MTT assays showed that JuA did not exhibit cytotoxic effects in concentrations from 0 to 100 μM when treating H9C2 cardiomyocyte cells, and JuA effectively reversed the inhibition of cell viability caused by isoproterenol (ISO). Cells pretreated with JuA showed effects on cell viability, morphological changes, light chain 3 conversion, and activation of PI3K/Akt/mTOR signaling. ISO significantly inhibited cell viability in a time- and dose-dependent manner, and JuA pretreatment could reverse the reduction of cell viability and ameliorate the injury of H9C2 cells induced by ISO. Total saponins from ZSS are effective protective agents for cardiomyocytes; they could significantly improve the morphology, increase cell viability, and decrease cell apoptosis of rat cardiomyocytes with oxidative injury.

Overall evidence strength for cardiovascular effects: Preclinical only; cell-based and animal studies. No human trials have been identified.

4.8 Neuroprotection Against Parkinson's Disease Models

Several reports have summarized the major components of jujube and their potential health benefits; however, studies focusing specifically on the neuroprotective activities of jujubosides A and B are relatively lacking. In a 2022 study, researchers aimed to reveal the mechanisms by which jujubosides A and B prevent the neurotoxic effects of 6-OHDA (a neurotoxin used to model Parkinson's disease) in SH-SY5Y and SK-N-SH cells.

Overall evidence strength for Parkinson's-related neuroprotection: In vitro preclinical only; highly preliminary.

5. Pharmacokinetics and Bioavailability

The bioavailability of jujuboside A was found to be 1.32% in rats, indicating only a trace amount of JuA is able to be absorbed. Further investigation revealed that its poor bioavailability was not caused by malabsorption but by the metabolic process. This finding is pharmacologically significant: the low oral bioavailability of intact jujuboside A means that hydrolysis products — principally jujubogenin — formed during intestinal processing are likely to be the biologically active species reaching systemic circulation and the central nervous system.

Jujuboside B and jujubogenin, hydrolysis products of primary saponins, may be the absorbed bioactive species responsible for sedative effects via GABA-A receptor modulation. Interaction network analysis has attributed the potential of jujubosides to changes in blood-brain barrier integrity, which has provided basic and theoretical data for the efficacy evaluation and mechanism of jujubosides.

The gut microbiota play an important role in this transformation. Research published in 2025 specifically characterized the in vitro biotransformation of Ziziphi Spinosae Semen saponins by gut microbiota from healthy and insomniac groups, indicating that differences in microbial composition may influence the extent of jujuboside metabolism and thus the bioactive fraction available to the host. The results of one study showed that changes in plasma and urine metabolites caused by insomnia were reversed after administration of ZSS, and these changes were mainly related to amino acid metabolism, especially phenylalanine metabolism.

6. Dosage Forms and Dosages Reported in Studies

Dosages in the published literature pertain predominantly to the seed extract, whole preparations, or multi-herb formulae rather than to purified jujuboside compounds. The following dosages are drawn directly from study reports:

• Animal studies (rodent), JuA oral dosing: In a CUMS rat depression model, JuA was administered orally at doses of 12.5 mg/kg (low), 25 mg/kg (medium), and 50 mg/kg (high) for 4 weeks.
• Animal studies, EEG/hippocampal model: JuA was used at concentrations of 0.05 g/L and 0.1 g/L via intracerebroventricular (icv) route in the rat hyperactivity model.
• Clinical trial product (ZSS extract capsules), active ingredient content: In the Australian feasibility RCT, the product was a 5-to-1 aqueous extract containing 65% ZS concentrated extract and 35% corn starch; HPLC analysis confirmed jujuboside A at 0.113 mg/g and jujuboside B at 0.124 mg/g in the extract.
• In vitro cardioprotective study: JuA did not exhibit cytotoxic effects in concentrations from 0 to 100 μM when treating H9C2 cells.

No standard human therapeutic dose for isolated jujubosides has been established in peer-reviewed clinical guidelines or pharmacopeial monographs as of the available literature.

7. Body Systems and Health Areas Associated with Jujubosides

• Central Nervous System: Sedative-hypnotic, anxiolytic, antidepressant, and neuroprotective activities via GABAergic and serotonergic modulation; studied in models of insomnia, anxiety, depression, and Alzheimer's disease.
• Cardiovascular System: Total saponins are effective protective agents for cardiomyocytes; they could significantly improve the morphology, increase cell viability, and decrease cell apoptosis in rat cardiomyocytes with oxidative injury.
• Immune and Inflammatory System: Total saponins inhibit the release of TNF-α from RAW264.7 macrophages induced by LPS.
• Oncology: Jujuboside B has shown anticancer activity in gastric and colorectal cancer cell lines, and in leukemia cells via the RIPK1/RIPK3/MLKL signaling pathway, in preclinical studies.
• Gut-Brain Axis: Jujuboside A not only regulates the expression of GABA receptor subunit mRNA, but also down-regulates the secretion of inflammatory cytokines related to the intestinal mucosal system, affects the cytokine network between nerve cells in the brain, and exerts its specific sedative-hypnotic effect through this gut-brain axis.

8. Safety Considerations and Interactions

8.1 Observed Adverse Events in Human Studies

In the randomized, placebo-controlled crossover clinical trial, eight participants reported 11 cases of minor adverse events. During the ZS treatment periods, adverse events included headaches (2 cases), dry mouth (1 case), and more frequent bowel motions (1 case). During the placebo periods, adverse events included headaches (1 case) and difficulty swallowing capsules (1 case). During the run-in and wash-out periods, there were also cases of common cold and cough. In all cases the events were mild and improved over time.

8.2 Tolerability Profile and General Safety Signal

Ziziphus spinosa is described in the published literature as a relatively safe sedative/hypnotic of choice for patients to manage insomnia. A meta-analysis found that FSZR (formula of Suanzaoren) caused fewer side effects than diazepam in RCTs. These observations pertain to whole seed preparations and the Suanzaoren formula; safety data for isolated, concentrated jujuboside fractions remain limited.

8.3 Potential Drug Interactions

Z. spinosa secondary metabolites have been shown to modulate GABAergic activity and the serotonergic system. This pharmacological profile implies a theoretical potential for pharmacodynamic interactions with GABAergic drugs (e.g., benzodiazepines, barbiturates, z-drugs), serotonergic agents (e.g., SSRIs, SNRIs), and other central nervous system depressants. A case report cited in the American Journal of Psychiatry (Stewart, 2004) is noted in the pharmacological literature in the context of a venlafaxine and sour date nut interaction. Robust clinical interaction data for isolated jujubosides are not currently available.

8.4 Bioavailability and Metabolism Considerations

The bioavailability of jujuboside A was only 1.32% in rats, and its poor bioavailability was attributed to metabolic processing rather than to malabsorption. This suggests the majority of pharmacological activity may depend on gut microbial and hepatic biotransformation, and that inter-individual variability in gut microbiome composition could substantially influence the biological response to ingested jujubosides.

8.5 Gaps in Safety Evidence

Pharmacological research has focused on jujuboside A and spinosin, with a slow process of characterizing other active compounds. A comprehensive quality evaluation of ZSS needs to be conducted to determine its pharmacological actions. Long-term human safety data, formal toxicology studies in humans, assessments in pregnant or lactating individuals, and evaluations in pediatric populations have not been published for isolated jujuboside preparations.

9. Summary of Evidence and Research Gaps

Jujubosides — primarily the A and B forms of this dammarane triterpenoid saponin family — represent the principal bioactive fraction of a seed (Semen Ziziphi Spinosae) with a documented history spanning over two millennia in East Asian traditional medicine. The mechanistic case for their neurological effects, particularly sedative-hypnotic and anxiolytic activity via GABAergic and serotonergic modulation, is supported by a substantial body of in vitro and animal research. Additional emerging preclinical evidence supports roles in neuroprotection, antidepressant activity, anti-inflammatory effects, cardioprotection, and anticancer activities, each mediated by distinct signaling pathways.

However, the translational gap between preclinical and clinical evidence remains wide. A role in the management of insomnia has been suggested in a review of pharmacological effects of the jujube seed, based on only 2 small clinical studies. The chemistry and psychopharmacology of the seeds of Z. jujuba has been reported, and whole extracts and constituent compounds have been evaluated in preclinical and clinical studies. The overall clinical evidence base — even for the best-studied indication of insomnia — applies to whole-seed preparations and multi-herb formulae, not to isolated jujuboside compounds. Standardization of preparations, establishment of optimal human dosing ranges, rigorous large-scale RCTs, and long-term safety surveillance studies are all needed before evidence-based conclusions can be drawn about the clinical efficacy of jujubosides as isolated agents.

References

• MedCrave: Pharmacological review of Ziziphus plants and jujuboside A & B compounds (2024)
• PMC: Sour Jujube (Ziziphus jujuba var. spinosa): A Bibliometric Review of Its Bioactive Profile, Health Benefits and Trends in Food and Medicine Applications
• MDPI Molecules: Comprehensive Chemical Composition Evaluation of Ziziphus jujuba var. spinosa Germplasm Resources
• PMC: Identification of Chemical Constituents in the Extract and Rat Serum from Ziziphus jujuba Mill by HPLC-PDA-ESI-MSn
• Frontiers in Pharmacology: Ziziphus jujuba Mill. var. spinosa Seed Ameliorates Insomnia in Rats by Regulating Metabolomics and Intestinal Flora Composition
• PMC (Evidence-Based Complementary and Alternative Medicine): Botanical and Traditional Uses and Phytochemical, Pharmacological, Pharmacokinetic, and Toxicological Characteristics of Ziziphi Spinosae Semen: A Review (2020)
• PMC: Jujuboside A prevents sleep loss-induced disturbance of hippocampal neuronal excitability and memory impairment in young APP/PS1 mice
• PMC: Research Advances in the Efficacy and Mechanism of Guipi Capsule in Reducing Insomnia
• ScienceDirect (Journal of Ethnopharmacology): Jujuboside A in ameliorating insomnia in mice via GABAergic modulation of the PVT (2025)
• PMC: The mechanism of simultaneous intake of Jujuboside A and B in the regulation of sleep at the hypothalamic level
• PMC: Inhibitory effects of jujuboside A on EEG and hippocampal glutamate in hyperactive rat
• PMC: Jujuboside A Regulates Calcium Homeostasis and Structural Plasticity to Alleviate Depression-Like Behavior via Shh Signaling in Immature Neurons
• PMC: Jujuboside A Protects H9C2 Cells from Isoproterenol-Induced Injury via Activating PI3K/Akt/mTOR Signaling Pathway
• PMC: Jujuboside A promotes Aβ clearance and ameliorates cognitive deficiency in Alzheimer's disease through activating Axl/HSP90/PPARγ pathway
• PMC: Antiamnesic and Neuroprotective Effects of an Aqueous Extract of Ziziphus jujuba Mill. on Scopolamine-Induced Cognitive Impairments in Rats
• PubMed: Jujuboside A promotes proliferation and neuronal differentiation of APPswe-overexpressing neural stem cells by activating Wnt/β-catenin signaling pathway (Neuroscience Letters, 2022)
• PMC (Molecules): Protective Effects of Jujubosides on 6-OHDA-Induced Neurotoxicity in SH-SY5Y and SK-N-SH Cells (2022)
• ACS Journal of Agricultural and Food Chemistry: Gastrointestinal Absorption and Metabolic Dynamics of Jujuboside A, A Saponin Derived from the Seed of Ziziphus jujuba
• ScienceDirect (Complementary Therapies in Medicine): Medicinal seeds Ziziphus spinosa for insomnia: A randomized, placebo-controlled, cross-over, feasibility clinical trial
• ScienceDirect (Phytomedicine): Ziziphus spinosa seeds for insomnia: A review of chemistry and psychopharmacology
• Frontiers in Pharmacology: Jujuboside B Inhibits the Proliferation of Breast Cancer Cell Lines by Inducing Apoptosis and Autophagy (2021)
• ACS Journal of Natural Products: Antitumor Activity of Jujuboside B and the Underlying Mechanism via Induction of Apoptosis and Autophagy
• Frontiers in Food Science and Technology: Effects of Ziziphus jujuba Mill. var. spinosa Seed mixture on sleep quality in pre-clinical and clinical studies (2026)
• Drugs.com Natural Products Database: Jujube Uses, Benefits & Dosage
• ResearchGate / Chinese Medicine (2025): Decoding multicomponent crosstalk: integrated pharmacodynamic-pharmacokinetic network of sour jujube seed